TLSI
TriSalus Life Sciences Inc.NASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$200.22M
P/E Ratio
—
EPS
$-1.42
Beta
0.56
52W High
$7.95
52W Low
$2.20
50-Day MA
$4.06
200-Day MA
$4.94
Dividend Yield
—
Profit Margin
-60.90%
Forward P/E
—
PEG Ratio
—
About TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.
Fundamentals
| Revenue (TTM) | $44.88M |
| Gross Profit (TTM) | $38.18M |
| EBITDA | $-27.44M |
| Operating Margin | -94.50% |
| Return on Equity | -496.20% |
| Return on Assets | -35.20% |
| Revenue/Share (TTM) | $1.02 |
| Book Value | $-0.68 |
| Price-to-Book | 15.68 |
| Price-to-Sales (TTM) | 4.46 |
| EV/Revenue | 3.983 |
| EV/EBITDA | -5.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.90% |
| Shares Outstanding | $61.42M |
| Float | $49.45M |
| % Insiders | 33.91% |
| % Institutions | 34.44% |
Historical Volatility
HV 10-Day
40.52%
HV 20-Day
34.62%
HV 30-Day
43.08%
HV 60-Day
61.80%
HV Rank
2.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.80 target)
1
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026